AMHR2

Celmatix Announces Breakthrough in Novel Oral Fertility Drug Program

Retrieved on: 
Tuesday, June 27, 2023

Celmatix Inc., the leading women’s health biotechnology company focused on ovarian biology, today announced the identification of promising early leads in its latest drug program, aimed at developing the world’s first oral FSH receptor (FSHR) agonist drug.

Key Points: 
  • Celmatix Inc., the leading women’s health biotechnology company focused on ovarian biology, today announced the identification of promising early leads in its latest drug program, aimed at developing the world’s first oral FSH receptor (FSHR) agonist drug.
  • Therefore, a successful oral FSHR drug must stimulate the FSH receptor without stimulating the thyroid hormone receptor (TSHR).
  • Early Celmatix data suggests that their unique, rationally designed compounds overcome this significant hurdle to drug development for this target.
  • Celmatix Chief Scientific Officer, Dr. Stephen Palmer, notes, “We are very pleased to see that several of our novel compounds demonstrate the desired potency and selectivity required for a successful oral FSH drug.

Celmatix Launches Novel PCOS Drug Program

Retrieved on: 
Thursday, April 13, 2023

Celmatix Inc., the leading women’s health biotech focused on ovarian biology, today announced its latest drug program, which is targeting melatonin receptors outside of the central nervous system (CNS).

Key Points: 
  • Celmatix Inc., the leading women’s health biotech focused on ovarian biology, today announced its latest drug program, which is targeting melatonin receptors outside of the central nervous system (CNS).
  • Despite its prevalence, no drug has ever been developed specifically to treat PCOS.
  • The Celmatix program is aimed at restoring ovarian function in a way that addresses the root cause of all these symptoms.
  • The novel program has emerged from a decade-long multi-omics initiative at the Company to understand the molecular and genetic mechanisms underlying ovarian health and conditions like PCOS.

Celmatix Appoints Seasoned Litigator Craig Bolton as General Counsel to Support Pipeline Expansion Strategy

Retrieved on: 
Wednesday, July 20, 2022

Celmatix Inc., the leading womens health biotech focused uniquely on ovarian biology, today announced that Craig Bolton has been appointed as General Counsel.

Key Points: 
  • Celmatix Inc., the leading womens health biotech focused uniquely on ovarian biology, today announced that Craig Bolton has been appointed as General Counsel.
  • Bolton joins the Celmatix executive team after representing the biotech as outside counsel since 2019 and will play a critical role in supporting the company in ongoing therapeutic pipeline expansion and progress of their lead AMHR2 agonist program.
  • Craig has been an excellent partner to Celmatix as outside counsel, and we are thrilled to have him now join our executive team.
  • Prior to joining Celmatix, Mr. Bolton was a partner at two nationally recognized law firms and an attorney at Wilson Sonsini Goodrich & Rosati.

Celmatix Announces Achievement of Key Preclinical Milestones in Premature Menopause Prevention Drug Program

Retrieved on: 
Monday, May 16, 2022

The program, which was a product of Celmatixs decade-long focus on identifying novel biomarkers and drug targets for womens health, has a planned first clinical indication in the prevention of premature menopause in women undergoing chemotherapy.

Key Points: 
  • The program, which was a product of Celmatixs decade-long focus on identifying novel biomarkers and drug targets for womens health, has a planned first clinical indication in the prevention of premature menopause in women undergoing chemotherapy.
  • Loss of ovarian function and menopause are accelerated by approximately 1.5 years for each month a woman receives chemotherapy treatment.
  • A century ago, the average life expectancy for women globally was under 50, so most women did not live long enough to experience menopause.
  • The milestone was triggered by Evotec and Bayer AG advancing a drug program, centered around a novel Celmatix-identified drug target, into hit-identification.

Celmatix Achieves Milestone for PCOS Drug Program

Retrieved on: 
Tuesday, January 18, 2022

Celmatix Inc., a biotechnology company focused on ovarian biology, today announced that a third milestone has been achieved in its five-year, multi-target alliance with Evotec .

Key Points: 
  • Celmatix Inc., a biotechnology company focused on ovarian biology, today announced that a third milestone has been achieved in its five-year, multi-target alliance with Evotec .
  • The milestone was triggered by Evotec and Bayer AG advancing a drug program, centered around a novel Celmatix-identified drug target, into hit-identification.
  • Worldwide, hundreds of millions of women are struggling with PCOS, the most common endocrine disorder in premenopausal women.
  • While the underlying cause of PCOS is largely unknown, genomic studies suggest a strong genetic connection.